Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | President and COO | July 08, 2024 | July 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date July 08, 2024 · Filed July 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2034-07-08 | Direct | 307,000 |
Reported balance
After 2024-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-08 · Grant · Acquired 307,000 · Balance 307,000 F1: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2020 Filed Mar 3, 2020 21:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 25,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008971 · form4.xml · nonDerivative · entry 4 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 9,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008971 · form4.xml · nonDerivative · entry 3 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008971 · form4.xml · nonDerivative · entry 2 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 4,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008971 · form4.xml · nonDerivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 21:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 274,200 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001127602-20-004609 · form4.xml · derivative · entry 2 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,200 Underlying: Common Stock · 274,200 shares Expires 2030-02-06 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 21:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 91,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004609 · form4.xml · derivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,400 Underlying: Common Stock · 91,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F2 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 9,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · derivative · entry 9 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,110 Underlying: Common Stock · 9,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F6 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 2,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · derivative · entry 8 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,595 Underlying: Common Stock · 2,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F5 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 4,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · derivative · entry 7 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,495 Underlying: Common Stock · 4,495 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F4 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 5,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · derivative · entry 6 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 8,639 | $5.51 | $47,600.89 |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · nonDerivative · entry 5 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,508 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 9,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · nonDerivative · entry 4 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · nonDerivative · entry 3 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 4,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · nonDerivative · entry 2 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 5,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009268 · form4.xml · nonDerivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:02 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 75,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004874 · form4.xml · derivative · entry 2 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,870 Underlying: Common Stock · 75,870 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:02 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 140,900 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001127602-19-004874 · form4.xml · derivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,900 Underlying: Common Stock · 140,900 shares Expires 2029-02-07 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/7/2020) and vests 1/48th per month for each month of service thereafter Read SEC document |
| August 01, 2018 Filed Feb 8, 2019 22:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004861 · form5.xml · nonDerivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,492 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 2,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · derivative · entry 9 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,393 Underlying: Common Stock · 2,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F6 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 4,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · derivative · entry 8 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,990 Underlying: Common Stock · 4,495 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F5 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 5,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · derivative · entry 7 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,807 Underlying: Common Stock · 5,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F4 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 2,929 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · derivative · entry 6 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2015 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2015 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 6,133 | $8.53 | $52,314.49 |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · nonDerivative · entry 5 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,492 F2 · kind: Withholding of a portion of vested shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · nonDerivative · entry 4 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 4,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · nonDerivative · entry 3 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 5,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · nonDerivative · entry 2 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,929 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009737 · form4.xml · nonDerivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 79,550 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001127602-18-005209 · form4.xml · derivative · entry 2 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,550 Underlying: Common Stock · 79,550 shares Expires 2028-02-08 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/8/2019) and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 28,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005209 · form4.xml · derivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,665 Underlying: Common Stock · 28,665 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F2 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| December 15, 2017 Filed Feb 12, 2018 22:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005197 · form5.xml · nonDerivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,597 Read SEC document |
| November 14, 2017 Filed Nov 14, 2017 23:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 2,000 | $9.48 | $18,961.80 |
DisclosureSEC source: 0001127602-17-032116 · form4.xml · nonDerivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,597 Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units (Phantom Stock) · Derivative | 4,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · derivative · entry 9 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,485 Underlying: Common Stock · 4,495 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F6 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units (Phantom Stock) · Derivative | 5,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · derivative · entry 8 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,614 Underlying: Common Stock · 5,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F5 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units (Phantom Stock) · Derivative | 2,928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · derivative · entry 7 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,929 Underlying: Common Stock · 2,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2015 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F4 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2015 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units (Phantom Stock) · Derivative | 2,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · derivative · entry 6 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2014 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2014 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 6,455 | $16.45 | $106,184.75 |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · nonDerivative · entry 5 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,597 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 4,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · nonDerivative · entry 4 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 5,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · nonDerivative · entry 3 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · nonDerivative · entry 2 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:52 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009397 · form4.xml · nonDerivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:30 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units (Phantom Stock) · Derivative | 11,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-005432 · form4.xml · derivative · entry 2 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,190 Underlying: Common Stock · 11,190 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:30 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 44,770 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001127602-17-005432 · form4.xml · derivative · entry 1 WADE JEFFREY L · CIK 0001225767 · EVP, Corp Adm Affairs and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,770 Underlying: Common Stock · 44,770 shares Expires 2027-02-09 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/9/2018) and vests 1/48th per month for each month of service thereafter Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.